C4 therapeutics highlights recent achievement in biogen collaboration

Watertown, mass., sept. 04, 2025 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner biogen has had its investigational new drug (ind) application for biib142 accepted by the u.s. food and drug administration (fda).
CCCC Ratings Summary
CCCC Quant Ranking